细胞因子诱导的杀伤细胞在肿瘤治疗中的作用

摘要/Abstract

摘要：细胞因子诱导的杀伤（CIK）细胞是用于肿瘤免疫治疗的主要免疫活性细胞。相关基础研究显示其对多种血液及实体肿瘤有显著杀伤活性，大量临床试验证实其对肿瘤患者有明确疗效且不良反应轻微。CIK细胞治疗肿瘤是一种前景广阔且安全的方法，因此建立规范的培养和应用标准十分重要。

高萌, 云升. 细胞因子诱导的杀伤细胞在肿瘤治疗中的作用[J]. 国际肿瘤学杂志, 2013, 40(12): 908-911.

GAO Meng, YUN Sheng. Functions of cytokine induced killer cells in oncotherapy[J]. Journal of International Oncology, 2013, 40(12): 908-911.

［1］ Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokineinduced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther, 2012, 12(6): 673684. ［2］ Pievani A, Borleri G, Pende D, et al. Dualfunctional capability of CD3+CD56+ CIK cells, a Tcell subset that acquires NK function and retains TCRmediated specific cytotoxicity. Blood, 2011, 118(12): 33013310. ［3］ Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cellviral biotherapy. Science, 2006, 311(5768): 17801784. ［4］ Franceschetti M, Pievani A, Borleri G, et al. Cytokineinduced killer cells are terminally differentiated activated CD8 cytotoxic TEMRA lymphocytes. Exp Hematol, 2009, 37(5): 616628. ［5］ Joshi PS, Liu JQ, Wang Y, et al. Cytokineinduced killer T cells kill immature dendritic cells by TCRindependent and perforindependent mechanisms. J Leukoc Biol, 2006, 80(6): 13451353. ［6］ Thanendrarajan S, Nowak M, Abken H, et al. Combining cytokineinduced killer cells with vaccination in cancer immunotherapy: more than one plus one?. Leuk Res, 2011, 35(9): 11361142. ［7］司玉玲, 庞华, 綦振家, 等. 耐药乳腺癌免疫治疗的实验研究. 天津医药, 2012, 40(4): 359362. ［8］李应林, 李宁, 李冉, 等. CIK对人肺腺癌耐顺铂细胞A549/DDP杀伤效应及耐药逆转作用. 遵义医学院学报, 2012, 35(5): 404406. ［9］ Wang YF, Kunda PE, Lin JW, et al. Cytokineinduced killer cells cocultured with complete tumor antigenloaded dendritic cells, have enhanced selective cytotoxicity on carboplatinresistant retinoblastoma cells. Oncol Rep, 2013, 29(5): 18411850. ［10］梅家转, 刘桂举, 张晓娟, 等. IL12增强CIK细胞对食管癌EC9706细胞的杀伤活性. 中国肿瘤生物治疗杂志, 2013, 20(2): 197200. ［11］ Rettinger E, Kuci S, Naumann I, et al. The cytotoxic potential of interleukin15stimulated cytokineinduced killer cells against leukemia cells. Cytotherapy, 2012, 14(1): 91103. ［12］ Pievani A, Belussi C, Klein C, et al. Enhanced killing of human Bcell lymphoma targets by combined use of cytokineinduced killer cell (CIK) cultures and antiCD20 antibodies. Blood, 2011, 117(2): 510518．［13］ Bonanno G, Iudicone P, Mariotti A, et al. Thymoglobulin, intederon7 and interleukin2 efficiently expand cytokineinduced killer (CIK) cells in clinicalgrade cultures. J Transl Med, 2010, (8): 129. ［14］ Nagaraj S, Ziske C, SchmidtWolf IG. Human cytokineinduced killer cells have enhanced in vitro cytolytic activity via nonviral interleukin2 gene transfer. Genet Vaccines Ther, 2004, 2(1): 12. ［15］ Kornacker M, Verneris M, Kornacker B, et al. The apoptotic and proliferative fate of cytokineinduced killer cells after redirection to tumor cells with bispecific Ab. Cytotherapy, 2006, 8(1): 1323. ［16］ Matin V, Pizzitola I, Agostoni V, et al. Cytokineinduced killer cells for cell therapy of acute myeloid leukemial improvement of their immune activity by expression of CD33specific chimeric receptors. Haematologica, 2010, 95(12): 21442152. ［17］ Huang X, Chen YT, Song HZ, et al. Cisplatin pretreatment enhances antitumor activity of cytokineinduced killer cells. World J Gastroenterol, 2011, 17(25): 30023011. ［18］ Yang Z, Zhang Q, Xu K, et al. Combined therapy with cytokineinduced killer cells and oncolytic adenovirus expressing IL12 induce enhanced antitumor activity in liver tumor model. PLoS One, 2012, 7(9): e44802. ［19］ Ma Y, Zhang Z, Tang L, et al. Cytokineinduced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy, 2012, 14(4): 483493. ［20］董毅, 朱太岗, 李月红, 等. CIK细胞与DCCIK 细胞抗肿瘤效应的对照研究. 中华全科医学, 2011, 9(12): 18441938. ［21］ Li X, Xu B, Wu J, et al. Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol, 2012, 14 (5): 102108. ［22］ Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells:first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol, 2011, 137(2): 305310. ［23］ Ren J, Di L, Song G, et al. Selections of appropriate regimen of highdose chemotherapy combined with adoptive cellular therapy with dendritic and cytokineinduced killer cells improved progressionfree and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin Transl Oncol, 2013, 15（10）： 780788. ［24］张澎, 张静, 刘亮, 等. CIK 治疗转移性肾癌的临床疗效评价及预后影响因素分析. 中国肿瘤临床, 2012, 39(10): 732735. ［25］ Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DCactivated CIKs to chemotherapy treatment in a single cohort of advanced nonsmallcell lung cancer patients. Cancer Immunology, Immunotherapy, 2013, 62, (1): 6573. ［26］彭大为, 李建旺, 元建华, 等. 自体DCCIK细胞联合培美曲塞治疗老年非小细胞肺癌的疗效与安全性. 中国免疫学杂志, 2012, 28(7): 648656. ［27］宋东, 杨晓玲, 冯慧晶, 等. DCCIK 联合化疗治疗消化道肿瘤临床疗效分析. 中国肿瘤临床, 2012, 39(9): 497501. ［28］王赛男, 高海燕, 潘欣, 等. DCCIK治疗对肾癌患者淋巴细胞亚群的影响. 中国肿瘤生物治疗杂志, 2012, 19(3): 309312. ［29］赵明明, 洪珞珈, 孙国勋, 等. DCCIK细胞联合治疗158例恶性肿瘤的免疫疗效观察. 哈尔滨医科大学学报, 2013, 47(1): 6066. ［30］ Zhao Q, Zhang H, Li Y, et al. Antitumor effects of CIK combined with oxaliplatin in human oxaliplatinresistant gastric cancer cells in vivo and in vitro. J Exp Cancer Res, 2010, 29: 118. ［31］ Qiu Y, Xu MB, Yun MM, et al. Hepatocellular carcinomaspecific immunotherapy with synthesized α1,3galactosyl epitopepulsed dendritic cells and cytokineinduced killer cells. World J Gastroenterol, 2011, 17(48): 52605266. ［32］ Qiu Y, Yun MM, Xu MB, et al. Pancreatic carcinomaspecific immunotherapy using synthesised alphagalactosyl epitopeactivated immuneresponders: findings from a pilot study. Int J Clin Oncol, 2013, 18(4): 657665. ［33］龚奕, 陈幸华, 张曦, 等. DCCIK细胞输注治疗急性髓细胞白血病50例分析. 重庆医学, 2011, 40(30): 30393041. ［34］杨皎娃, 邓琦, 李玉明. DCCIK共培养在AL化疗后免疫治疗中的应用及其对NKG2D表达的影响. 山东医药, 2013, 53(2): 13. ［35］ Chang C, Yang B, Zhang L, et al. Curative effect of decitabine combined with cytokineinduced killer cells in two elderly patients with acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2013, 21(1): 6267. ［36］ Tang H, Sampath P, Yan X, et al. Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination. Gene Ther, 2013, 20(7): 770778.

[1]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[3]	张文馨, 夏泠, 彭晋, 周福祥.甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[4]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇.信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[5]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[6]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[7]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[8]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[9]	崔腾璐, 吕璐, 孙鹏飞.放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[10]	李开春, 丁昌利, 于文艳.安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[11]	过慈良, 江春平, 吴俊华.肠道菌群与肿瘤免疫治疗[J]. 国际肿瘤学杂志, 2023, 50(7): 432-436.
[12]	陈秋, 王雷, 王明琦, 张梅.恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[13]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	顾安琴, 龙金华, 金风.鼻咽癌免疫治疗的临床研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 299-303.
[15]	邢明泉, 葛洪峰, 张丽侠, 韩浩, 吴维霞.疑似免疫性血小板减少症的侵袭性自然杀伤细胞白血病1例[J]. 国际肿瘤学杂志, 2023, 50(5): 318-320.

细胞因子诱导的杀伤细胞在肿瘤治疗中的作用

Functions of cytokine induced killer cells in oncotherapy

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价